ORGS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ORGS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Orgenesis has the Growth Rank of 1.
GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:
1. 5-year revenue growth rate, the higher, the better.A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.
GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.
Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.
For the Biotechnology subindustry, Orgenesis's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Orgenesis's Growth Rank distribution charts can be found below:
* The bar in red indicates where Orgenesis's Growth Rank falls into.
Thank you for viewing the detailed overview of Orgenesis's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Jacob Safier | 10 percent owner | C/O THE WOLFSON GROUP, ONE STATE STREET PLAZA 29TH FLOOR, NEW YORK NY 10004 |
Elliot Maltz | officer: Chief Financial Officer | C/O GELESIS, INC., 501 BOYLSTON ST., SUITE 6102, BOSTON MA 02116 |
Efrat Assa Kunik | officer: Chief Development Officer | C/O ORGENESIS INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876 |
David Sidransky | director | JOHNS HOPKINS UNIVERSITY, 720 RUTLAND AVENUE, BALTIMORE MD 21205 |
Mario Philips | director | C/O ATMI, INC, DANBURY CT 06810 |
Sarah Ferber | officer: Chief Scientific Officer | 17B HAHASKALA STREET, TEL AVIV L3 67890 |
Guy Yachin | director | 7 ORCHARD WAY N, POTOMAC MD 20854 |
Yaron Adler | director | 4 HA'NECHOSHET ST., RAMAT HA'CHAYAL, TEL AVIV L3 69710 |
Vered Caplan | officer: CEO | 20 HA'ETZEL STREET, PO BOX 9118 RAMAT EFAL, KIRYAT ONO L3 55280 |
Universite Libre De Bruxelles | 10 percent owner | AVENUE F, ROOSEVELT, 50, BRUSSELS C9 1050 |
Olivier Belenger | 10 percent owner | DIEWEG, 69, BRUSSELS C9 1070 |
Ii Sa Theodorus | 10 percent owner | ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070 |
Sca Theodorus | 10 percent owner | ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070 |
Denis Bedoret | officer: See Remarks | 48, RUE AUGUSTE PICCARD, GOSSELIES C9 6041 |
Ashish Nanda | director | 2301, 23RD FLOOR, TIFFANY TOWERS, CLUSTER W, JLT, DUBAI, UAE, DUBAI C0 4452 |
From GuruFocus
By sperokesalga sperokesalga • 05-30-2023
By Marketwired • 09-06-2023
By GuruFocus Research • 02-08-2024
By Marketwired • 08-11-2023
By Marketwired • 07-11-2023
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
By Marketwired • 08-08-2024
By GlobeNewswire • 10-31-2023
By Marketwired • 11-02-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.